Monday, December 15, 2014
DaVita HealthCare Partners, a U.S. innovative healthcare community, has announced that two of its business units, DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research, will merge capabilities to further expand its clinical research and data analytics services, specifically in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as primary care and chronic disease patients treated in an integrated care organization.
The Pulse on Patient Recruitment by Ashley Tointon
Healthcare technology has evolved and has created efficiencies in a variety of healthcare settings.
Anergis, a Swiss-based company developing proprietary ultra-fast allergy vaccines, has begun a phase II trial designed to finalize the dose selection for the phase III study of AllerT. AllerT is Anergis´ lead vaccine against birch pollen allergy that originated from the company´s proprietary Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, long-peptide immunotherapeutics designed for an ultra-fast, safe and long-lasting treatment of allergy patients.
CRF Health, a Plymouth Meeting, Pa.-based global provider of eCOA solutions for the life sciences Industry, has announced two new additions to the company’s executive leadership team as the organization continues to invest in a deeper and broader management structure to position the business for future growth.
The ALS Association, a national nonprofit organization based in Wash. D.C., has awarded $326,662 in research funds to expand ongoing natural history studies in order to further understand the most common genetic cause of ALS, in preparation for clinical trials in those whose disease is affected by this gene.
U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) have introduced a bill to create a new drug approval pathway to streamline access and encourage innovation and development of potentially lifesaving antibiotic drugs for patients, particularly Veterans who have encountered antibiotic-resistant bacteria while overseas.
Three new biomarker companies have been selected to work with the Early Diagnosis Consortium, a collaboration between Cancer Research U.K., its commercial arm, Cancer Research Technology, and Abcodia, a specialist company engaged in the validation of biomarkers for the early detection and screening of cancer.